Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
D001545:Benserazide / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D007980:Levodopa / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D013997:Time Factors
D006834:Hydrazines; D010648:Phenylacetates; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D001545:Benserazide; D006719:Homovanillic Acid